Phase Ib Trial of IRX-2 Plus Durvalumab in Patients with Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma
ORAL ONCOLOGY(2024)
Key words
Head and neck squamous cell carcinoma,IRX-2,Durvalumab,Tumor infiltrating lymphocytes,Programmed death ligand-1
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined